In line with these findings, we provided evidence that a number of HDACIs, by altering StAR acetylation patterns, are capable of decreasing StAR, aromatase, and E2 levels in ER+/PR+ BC cells [23]. This evidence concerns the gene CYP19A1 and breast cancer.